

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

AMENDMENT

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

In the Claims:


Please amend claims 1-4 as follows.

Please cancel claims 11-15 without prejudice or waiver.

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

L_1 is a bond;

L_2 is a bond, $-CH_2-$, or $-O-$;

A is phenyl substituted with 0-3 R^{11} and 0-1 R^{12} ;

B is phenyl substituted with 0-3 R^{11} and 0-1 R^{12} ;

X^1 , X^2 , X^3 and X^4 independently represent CR^1 , CR^2 , or CR^3 ;

R^1 is H, $-NH_2$, $-NH(C_1-C_3 \text{ alkyl})$, $-N(C_1-C_3 \text{ alkyl})_2$, $-C(=NH)NH_2$,

$-NHC(=NH)NH_2$, $-C(O)NH_2$, $-CH_2NH_2$, $-CH_2NH(C_1-C_3 \text{ alkyl})$,

$-CH_2N(C_1-C_3 \text{ alkyl})_2$, $-CH_2CH_2NH_2$, $-CH_2CH_2NH(C_1-C_3 \text{ alkyl})$,

$-CH_2CH_2N(C_1-C_3 \text{ alkyl})_2$, $-C(=NR^8)NR^7R^9$, $-NHC(=NR^8)NR^7R^9$,

$-ONHC(=NR^8)NR^7R^9$, $-NR^8CH(=NR^7)$, $-C(=NR^{8a})NR^7R^9$, $-NHC(=NR^{8a})NR^7R^9$,

$-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-S(O)_pNR^8R^9$, F, Cl, Br, I, OCF_3 , CF_3 , OR^a , SR^a , CN or

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

C₁₋₆ alkyl substituted with 1 R^{1a};

R^{1a} is -C(=NR⁸)NR⁷R⁹, -NHC(=NR⁸)NR⁷R⁹, -ONHC(=NR⁸)NR⁷R⁹,
-NR⁸CH(=NR⁷), -NR⁷R⁸, -C(O)NR^{7a}R⁸, -S(O)_pNR⁸R⁹, F, OCF₃, CF₃, OR^a, SR^a, or
CN;

R² is H, F, Cl, Br, I, OCF₃, CF₃, OR^a, SR^a, CN, NO₂, -NR⁷R⁸, -C(O)NR^{7a}R⁸,
-NR¹⁰C(O)R^b, -S(O)_pNR⁸R⁹, -S(O)R^c, -S(O)₂R^c, C₁₋₆ alkyl substituted with 0-2 R^{2a},
C₂₋₆ alkenyl substituted with 0-2 R^{2a}, C₂₋₆ alkynyl substituted with 0-2 R^{2a}, or -(CH₂)_r-
C₃₋₁₀ carbocycle substituted with 0-3 R^{2b};

each R^{2a} is, independently at each occurrence, H, F, OCF₃, CF₃, OR^a, SR^a, CN,
-NR⁷R⁸, -C(O)NR^{7a}R⁸, -NR¹⁰C(O)R^b, -S(O)_pNR⁸R⁹, -S(O)R^c, or -S(O)₂R^c;

each R^{2b} is, independently at each occurrence, H, F, Cl, Br, I, OR^a, SR^a, CN,
NO₂, CF₃, -SO₂R^c, -NR⁷R⁸, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl,
C₁₋₄ haloalkyl, C₁₋₄ haloalkyloxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(O)-, or
C₁₋₄ alkyl-C(O)NH-;

R³ is H, F, Cl, Br, I, OCF₃, CF₃, OR^a, SR^a, CN, NO₂, -NR⁷R⁸, -C(O)NR^{7a}R⁸,
-NR¹⁰C(O)R^b, -S(O)_pNR⁸R⁹, -S(O)R^c, -S(O)₂R^c, C₁₋₆ alkyl substituted with 0-2 R^{3a},
C₂₋₆ alkenyl substituted with 0-2 R^{3a}, C₂₋₆ alkynyl substituted with 0-2 R^{3a}, or -(CH₂)_r-
C₃₋₁₀ carbocycle substituted with 0-3 R^{3b};

each R^{3a} is, independently at each occurrence, H, F, OCF₃, CF₃, OR^a, SR^a, CN,
-NR⁷R⁸, -C(O)NR^{7a}R⁸, -NR¹⁰C(O)R^b, -S(O)_pNR⁸R⁹, -S(O)R^c, or -S(O)₂R^c;

each R^{3b} is, independently at each occurrence, H, F, Cl, Br, I, OR^a, SR^a, CN,
NO₂, CF₃, -SO₂R^c, -NR⁷R⁸, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl,
C₁₋₄ haloalkyl, C₁₋₄ haloalkyloxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(O)-, or
C₁₋₄ alkyl-C(O)NH-;

R⁴ is phenyl substituted with 0-3 R^{4b};

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Br, I, CN, NO₂, CF₃,
-C(O)OR^a, -SO₂R^c, -NR⁷R⁸, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

C₁₋₄ haloalkyl, C₁₋₄ haloalkyloxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(O)-, C₁₋₄ alkyl-C(O)NH-, -C(O)NR^{7a}R⁸, -NR¹⁰C(O)R^b, -NR¹⁰S(O)₂NR⁸R⁹, or -S(O)₂NR⁸R⁹;

R⁵ is H, C₁₋₄ haloalkyl, or C₁₋₆ alkyl substituted with 0-3 R^{5a};

each R^{5a} is, independently at each occurrence, H, C₁₋₄ alkyl, OR^a, F, =O, CF₃, CN, -C(O)R^a, -C(O)OR^a, -C(O)NR^{7a}R⁸, or -S(O)_pR^c;

each R⁶ is, independently at each occurrence, H, C₁₋₄ alkyl, -(CH₂)_rC(O)OR^a, -(CH₂)_rS(O)₂NR^{7a}R⁸, or -(CH₂)_rOR^a;

each R^{6a} is, independently at each occurrence, H or C₁₋₄ alkyl;

each R⁷ is, independently at each occurrence, H, C₁₋₆ alkyl, -(CH₂)_n-phenyl, (C₁₋₆ alkyl)C(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-C(O)-, (C₃₋₆ cycloalkyl)-C₀₋₄ alkyl-C(O)-, (C₁₋₄ alkyl)OC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-OC(O)-, (C₁₋₄ alkyl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-, (C₆₋₁₀ aryl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-, (C₁₋₆ alkyl)-NHC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-NHC(O)-, (C₁₋₆ alkyl)-S(O)₂-, (C₆₋₁₀ aryl)-(C₀₋₄ alkyl)-S(O)₂-, (C₁₋₆ alkyl)₂NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C₁₋₆ alkyl)NC(O)-, or (benzyl)(C₁₋₆ alkyl)NC(O)-, wherein said phenyl and aryl are substituted with 0-2 R^f;

each R^{7a} is, independently at each occurrence, H, C₁₋₄ alkyl substituted with 0-2 R^{7b} or 0-2 R^{7c}, or -(CH₂)_r-C₃₋₁₀ carbocycle substituted with 0-3 R^f;

each R^{7b} is, independently at each occurrence, =O, OR^g, F, Cl, Br, I, CN, NO₂, -NR⁷R⁸, -C(O)R^g, -C(O)OR^g, -NR⁸C(O)R^g, -C(O)NR⁸R⁹, -NR⁸C(O)NR⁸R⁹, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, or -(CF₂)_rCF₃;

each R^{7c} is, independently at each occurrence, C₃₋₁₀ carbocycle substituted with 0-3 R^f;

each R⁸ is, independently at each occurrence, H, C₁₋₆ alkyl, or -(CH₂)_n-phenyl;

each R^{8a} is, independently at each occurrence, H, OH, C₁₋₆ alkyl, -(CH₂)_n-phenyl, (C₁₋₆ alkyl)C(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-C(O)-,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

(C₃₋₆ cycloalkyl)-C₀₋₄ alkyl-C(O)-, (C₁₋₄ alkyl)OC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-OC(O)-, (C₁₋₄ alkyl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-, (C₆₋₁₀ aryl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-, (C₁₋₆ alkyl)-NHC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-NHC(O)-, (C₁₋₆ alkyl)-S(O)₂-, (C₆₋₁₀ aryl)-(C₀₋₄ alkyl)-S(O)₂-, C₁₋₄ alkoxy, (C₁₋₄ alkyl)C(O)O-, or (C₆₋₁₀ aryl)-(C₀₋₄ alkyl)-C(O)O-; wherein said phenyl and aryl are substituted with 0-2 R^f;

each R⁹ is, independently at each occurrence, H, C₁₋₆ alkyl, or -(CH₂)_n-phenyl;

each R¹⁰ is, independently at each occurrence, H, C₁₋₆ alkyl substituted with 0-2 R^{10a}, C₂₋₆ alkenyl substituted with 0-2 R^{10a}, C₂₋₆ alkynyl substituted with 0-2 R^{10a}, (C₁₋₆ alkyl)C(O)-, (C₃₋₆ cycloalkyl)C₁₋₃ alkyl-C(O)-, (C₃₋₆ cycloalkyl)C(O)-, phenyl-C(O)-, benzyl-C(O)-, benzyl-S(O)₂-, (C₁₋₆ alkyl)NHC(O)-, (C₁₋₆ alkyl)₂NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C₁₋₆ alkyl)NC(O)-, (benzyl)(C₁₋₆ alkyl)NC(O)-, (C₁₋₆ alkyl)-S(O)₂-, phenyl-S(O)₂-, or -(CH₂)_r-C₃₋₁₀ carbocycle substituted with 0-3 R^d;

each R^{10a} is, independently at each occurrence, H, C₁₋₄ alkyl, OR^a, Cl, F, Br, I, =O, CF₃, CN, NO₂, -C(O)R^a, -C(O)OR^a, -C(O)NR^{7a}R⁸, or -S(O)_pR^c;


each R¹¹ is, independently at each occurrence, H, =O, -(CH₂)_r-OR^a, F, Cl, Br, I, CN, NO₂, -(CH₂)_r-NR⁷R⁸, -C(O)R^a, -C(O)OR^a, -NR⁸C(O)R^a, -NR⁸C(O)OR^a, -C(O)NR^{7a}R⁸, -NR⁸C(O)NR⁸R⁹, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, -(CF₂)_rCF₃, C₁₋₆ alkyl substituted with 0-2 R^{11a}, C₂₋₆ alkenyl substituted with 0-2 R^{11a}, C₂₋₆ alkynyl substituted with 0-2 R^{11a}, C₁₋₆ alkyl substituted with 0-2 R^{11b}, C₂₋₆ alkenyl substituted with 0-2 R^{11b}, or C₂₋₆ alkynyl substituted with 0-2 R^{11b};

each R^{11a} is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO₂, -NR⁷R⁸, -C(O)R^a, -C(O)OR^a, -NR⁸C(O)R^a, -C(O)NR^{7a}R⁸, -NR⁸C(O)NR⁸R⁹, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, or -(CF₂)_rCF₃;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

each R^{11b} is, independently at each occurrence, C_{3-10} carbocycle substituted with 0-3 R^d ; ~~or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p, and substituted~~ 0-3 R^d ;

each R^{12} is, independently at each occurrence, OR^{12a} , $-C(O)NR^{7a}R^8$, $-(CH_2)_rCO_2R^{12a}$, $-(CH_2)_rSO_3H$, $-OSO_3H$, $-(CH_2)_rPO_3H$, $-OPO_3H_2$, $-PO_3H_2$, $-NHPO_3H_2$, $-NHCOCF_3$, $-NHOSO_2CF_3$, $-CONHNHOSO_2CF_3$, $-C(CF_3)_2OH$, $-SO_2NHR^{12a}$, $-CONHSO_2NHR^{12a}$, $-SO_2NHCOR^{12a}$, $-SO_2NHCO_2R^{12a}$, $-CONHSO_2R^{12b}$, $-NHOSO_2R^{12b}$, $-CONHOR^{12b}$,



each R^{12a} is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_rC_{3-10}$ carbocycle substituted with 0-3 R^d ; ~~or $-(CH_2)_r$ 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p, and substituted with 0-3 R^d ;~~

each R^{12b} is, independently at each occurrence, C_{1-6} alkyl substituted with 0-2 R^{12c} , C_{2-6} alkenyl substituted with 0-2 R^{12c} , C_{2-6} alkynyl substituted with R^{12c} , or $-(CH_2)_rC_{3-10}$ carbocycle substituted with 0-3 R^{12c} ; ~~or $-(CH_2)_r$ 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p, and substituted with 0-3 R^{12c} ;~~

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3 , OCF_3 , CN, NO_2 , OR^a , $-CO_2R^a$, $-NR^7R^8$, $-SO_2R^c$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

~~-(CH₂)_r-C₃₋₁₀ carbocycle substituted with 0-3 R^d; or -(CH₂)_r-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p; and substituted with 0-3 R^d;~~

R¹³ is H, C₁₋₄ alkyl, (NR⁷R⁸)C₁₋₄ alkyl, (SR^c)C₁₋₄ alkyl, (OR^a)C₁₋₄ alkyl, OR^a, F, CF₃, -C(O)R^a, -C(O)OR^a, -C(O)NR^{7a}R⁸, or -S(O)_pR^c;

R¹⁴ is H, C₁₋₄ alkyl, (NR⁷R⁸)C₁₋₄ alkyl, (SR^c)C₁₋₄ alkyl, (OR^a)C₁₋₄ alkyl, OR^a, F, CF₃, -C(O)R^a, -C(O)OR^a, -C(O)NR^{7a}R⁸, or -S(O)_pR^c;

alternately, R¹³ and R¹⁴ may be taken together to be =O;

R¹⁵ is H or C₁₋₄ alkyl;

R¹⁶ is H, C₁₋₄ alkyl, benzyl, C₁₋₄ alkyl-C(O)-, C₁₋₄ alkyl-S(O)₂-, or C₁₋₄ alkyl-OC(O)-;

each R^a is, independently at each occurrence, H, C₁₋₄ alkyl, -(CH₂)_r-CO₂R^g, -(CH₂)_r-C₃₋₇ cycloalkyl, or -(CH₂)_r-C₆₋₁₀ aryl, wherein said aryl is substituted with 0-2 R^f;

each R^b is, independently at each occurrence, CF₃, OH, C₁₋₄ alkoxy, C₁₋₆ alkyl, or -(CH₂)_r-C₃₋₁₀ carbocycle substituted with 0-2 R^d;

each R^c is, independently at each occurrence, C₁₋₄ alkyl, C₆₋₁₀ aryl, or (C₆₋₁₀ aryl)-C₁₋₄ alkyl, wherein said aryl is substituted with 0-2 R^d;

each R^d is, independently at each occurrence, H, =O, OR^a, F, Cl, Br, I, CN, NO₂, -NR⁷R⁸, -C(O)R^a, -C(O)OR^a, -NR⁸C(O)R^a, -C(O)NR^{7a}R⁸, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, -(CF₂)_rCF₃, C₁₋₆ alkyl substituted with 0-2 R^e, C₂₋₆ alkenyl substituted with 0-2 R^e, or C₂₋₆ alkynyl substituted with 0-2 R^e;

each R^e is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO₂, -NR⁸R⁹, -C(O)R^a, -C(O)OR^a, -NR⁸C(O)R^a, -C(O)NR^{7a}R⁸, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, or -(CF₂)_rCF₃;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl, Br, I, CN, NO₂,
-NR⁸R⁹, -C(O)R^g, -C(O)OR^g, -NR⁸C(O)R^g, -C(O)NR⁸R⁹, -SO₂NR⁸R⁹,
-NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃,
-S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, -(CF₂)_rCF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, or
C₂-C₆ alkynyl;

each R^g is, independently at each occurrence, H, C₁₋₆ alkyl, or
-(CH₂)_n-phenyl;


n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

provided that when L₁ is a bond and A is phenyl or a 6-membered aromatic
~~N-heterocycle~~, then ring A is not substituted ortho to L₁ with OH, halogen, -CO₂H,
-C(O)O-C₁₋₄ alkyl, -O-phenyl, -O-benzyl, -NR⁷R⁸, -CH₂OR^a, haloalkyl, -S-C₁₋₄ alkyl,
or -NHSO₂-C₁₋₄ alkyl.

2. (Currently amended) A compound according to Claim 1, wherein the compound
is of Formula (Ia):



or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

A is phenyl substituted with 0-2 R¹¹ and 0-1 R¹²;

B is phenyl substituted with 0-2 R¹¹ and 0-1 R¹²;

R¹ is H, -NH₂, -NH(C₁-C₃ alkyl), -N(C₁-C₃ alkyl)₂, -C(=NH)NH₂,
-NHC(=NH)NH₂, -C(O)NH₂, -CH₂NH₂, -CH₂NH(C₁-C₃ alkyl),
-CH₂N(C₁-C₃ alkyl)₂, -CH₂CH₂NH₂, -CH₂CH₂NH(C₁-C₃ alkyl),
-CH₂CH₂N(C₁-C₃ alkyl)₂, -C(=NR⁸)NR⁷R⁹, -NHC(=NR⁸)NR⁷R⁹,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

-ONHC(=NR⁸)NR⁷R⁹, -NR⁸CH(=NR⁷), -C(=NR^{8a})NR⁷R⁹, -NHC(=NR^{8a})NR⁷R⁹,
-NR⁷R⁸, -C(O)NR^{7a}R⁸, -S(O)_pNR⁸R⁹, F, Cl, Br, I, OCF₃, CF₃, OR^a, SR^a, CN or
C₁₋₆ alkyl substituted with 1 R^{1a};

R^{1a} is -C(=NR⁸)NR⁷R⁹, -NHC(=NR⁸)NR⁷R⁹, -ONHC(=NR⁸)NR⁷R⁹,
-NR⁸CH(=NR⁷), -NR⁷R⁸, -C(O)NR^{7a}R⁸, -S(O)_pNR⁸R⁹, F, OCF₃, CF₃, OR^a, SR^a, or
CN;

R² is H, F, OR^a, CN, -NR⁷R⁸, -C(O)NR^{7a}R⁸, -NR¹⁰C(O)R^b, -S(O)_pNR⁸R⁹,
-S(O)R^c, -S(O)₂R^c, C₁₋₆ alkyl substituted with 0-2 R^{2a}, or -(CH₂)_r-C₃₋₇ carbocycle
substituted with 0-2 R^{2b};

each R^{2a} is, independently at each occurrence, H, F, OCF₃, CF₃, OR^a, SR^a, CN,
-NR⁷R⁸, -C(O)NR^{7a}R⁸, -NR¹⁰C(O)R^b, -S(O)_pNR⁸R⁹, -S(O)R^c, or -S(O)₂R^c;

each R^{2b} is, independently at each occurrence, H, F, OR^a, SR^a, CN, NO₂, CF₃,
-SO₂R^c, -NR⁷R⁸, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₄
haloalkyl, C₁₋₄ haloalkyloxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(O)-,
or C₁₋₄ alkyl-C(O)NH-;

R⁴ is phenyl substituted with 0-3 R^{4b};

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Br, CN, NO₂,
CF₃, -C(O)OR^a, -SO₂R^c, -NR⁷R⁸, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆
cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyloxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-,
C₁₋₄ alkyl-C(O)-, C₁₋₄ alkyl-C(O)NH-, -C(O)NR^{7a}R⁸, -NR¹⁰C(O)R^b,
-NR¹⁰S(O)₂NR⁸R⁹, or -S(O)₂NR⁸R⁹;

R⁵ is H, C₁₋₄ haloalkyl, or C₁₋₆ alkyl substituted with 0-2 R^{5a};

each R⁶ is, independently at each occurrence, H, C₁₋₄ alkyl, -(CH₂)_rC(O)OR^a,
-(CH₂)_rS(O)₂NR^{7a}R⁸, or -(CH₂)_rOR^a;

each R^{6a} is, independently at each occurrence, H or C₁₋₄ alkyl;

each R⁷ is, independently at each occurrence, H, C₁₋₆ alkyl, -(CH₂)_n-phenyl,
(C₁₋₆ alkyl)C(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-C(O)-, (C₃₋₆ cycloalkyl)-C₀₋₄ alkyl-C(O)-,
(C₁₋₄ alkyl)OC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-OC(O)-,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

(C₁₋₄ alkyl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-, (C₆₋₁₀ aryl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-,
(C₁₋₆ alkyl)-NHC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-NHC(O)-, (C₁₋₆ alkyl)-S(O)₂-,
(C₆₋₁₀ aryl)-(C₀₋₄ alkyl)-S(O)₂-, (C₁₋₆ alkyl)₂NC(O)-, phenyl-NHC(O)-,
benzyl-NHC(O)-, (phenyl)(C₁₋₆ alkyl)NC(O)-, or (benzyl)(C₁₋₆ alkyl)NC(O)-, wherein
said phenyl and aryl are substituted with 0-2 R^f;

each R^{7a} is, independently at each occurrence, H, C₁₋₄ alkyl substituted with 0-1
R^{7b} or 0-1 R^{7c}, -(CH₂)_r-C₃₋₇ cycloalkyl substituted with 0-2 R^f, or -(CH₂)_r-phenyl
substituted with 0-3 R^f;

each R^{7b} is, independently at each occurrence, =O, OR^g, F, Cl, Br, I, CN, NO₂,
-NR⁷R⁸, -C(O)R^g, -C(O)OR^g, -NR⁸C(O)R^g, -C(O)NR⁸R⁹, -NR⁸C(O)NR⁸R⁹,
-SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl,
-S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, or -(CF₂)_rCF₃;

R^{7c} is C₃₋₁₀ carbocycle substituted with 0-3 R^f;

each R⁸ is, independently at each occurrence, H, C₁₋₆ alkyl, or -(CH₂)_n-phenyl;

each R^{8a} is, independently at each occurrence, H, OH, C₁₋₆ alkyl,
-(CH₂)_n-phenyl, (C₁₋₆ alkyl)C(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-C(O)-,
(C₃₋₆ cycloalkyl)-C₀₋₄ alkyl-C(O)-, (C₁₋₄ alkyl)OC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-OC(O)-,
(C₁₋₄ alkyl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-, (C₆₋₁₀ aryl)-C(O)O-(C₁₋₄ alkyl)-OC(O)-,
(C₁₋₆ alkyl)-NHC(O)-, (C₆₋₁₀ aryl)-C₀₋₄ alkyl-NHC(O)-, (C₁₋₆ alkyl)-S(O)₂-,
(C₆₋₁₀ aryl)-(C₀₋₄ alkyl)-S(O)₂-, C₁₋₄ alkoxy, (C₁₋₄ alkyl)C(O)O-, or
(C₆₋₁₀ aryl)-(C₀₋₄ alkyl)-C(O)O-; wherein said phenyl and aryl are substituted with 0-2
R^f;

each R⁹ is, independently at each occurrence, H, C₁₋₆ alkyl, or -(CH₂)_n-phenyl;

each R¹⁰ is, independently at each occurrence, H, C₁₋₆ alkyl substituted with 0-2
R^{10a}, C₂₋₆ alkenyl substituted with 0-2 R^{10a}, C₂₋₆ alkynyl substituted with 0-2 R^{10a},
(C₁₋₆ alkyl)C(O)-, (C₃₋₆ cycloalkyl)C₁₋₃ alkyl-C(O)-, (C₃₋₆ cycloalkyl)C(O)-,
phenyl-C(O)-, benzyl-C(O)-, benzyl-S(O)₂-, (C₁₋₆ alkyl)NHC(O)-, (C₁₋₆ alkyl)₂NC(O)-,
phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C₁₋₆ alkyl)NC(O)-,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

(benzyl)(C₁₋₆ alkyl)NC(O)-, (C₁₋₆ alkyl)-S(O)₂-, phenyl-S(O)₂-, or -(CH₂)_r-C₃₋₁₀ carbocycle substituted with 0-3 R^d;

each R^{10a} is, independently at each occurrence, H, C₁₋₄ alkyl, OR^a, Cl, F, Cl, Br, I, =O, CF₃, CN, NO₂, -C(O)R^a, -C(O)OR^a, -C(O)NR^{7a}R⁸, or -S(O)_pR^c;

each R¹¹ is, independently at each occurrence, H, =O, -(CH₂)_r-OR^a, F, Cl, Br, I, CN, NO₂, -(CH₂)_r-NR⁷R⁸, -C(O)R^a, -C(O)OR^a, -NR⁸C(O)R^a, -NR⁸C(O)OR^a, -C(O)NR^{7a}R⁸, -NR⁸C(O)NR⁸R⁹, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, -(CF₂)_rCF₃, C₁₋₆ alkyl substituted with 0-2 R^{11a}, C₂₋₆ alkenyl substituted with 0-2 R^{11a}, C₂₋₆ alkynyl substituted with 0-2 R^{11a}, C₁₋₆ alkyl substituted with 0-2 R^{11b}, C₂₋₆ alkenyl substituted with 0-2 R^{11b}, or C₂₋₆ alkynyl substituted with 0-2 R^{11b};


each R^{11a} is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO₂, -NR⁷R⁸, -C(O)R^a, -C(O)OR^a, -NR⁸C(O)R^a, -C(O)NR^{7a}R⁸, -NR⁸C(O)NR⁸R⁹, -SO₂NR⁸R⁹, -NR⁸SO₂NR⁸R⁹, -NR⁸SO₂-C₁₋₄ alkyl, -NR⁸SO₂CF₃, -NR⁸SO₂-phenyl, -S(O)₂CF₃, -S(O)_p-C₁₋₄ alkyl, -S(O)_p-phenyl, or -(CF₂)_rCF₃;

each R^{11b} is, independently at each occurrence, C₃₋₁₀ carbocycle substituted with 0-3 R^d; ~~or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p, and substituted 0-3 R^d;~~

each R¹² is, independently at each occurrence, OR^{12a}, -C(O)NR^{7a}R⁸, -(CH₂)_rCO₂R^{12a}, -(CH₂)_rSO₃H, -OSO₃H, -(CH₂)_rPO₃H, -OPO₃H₂, -PO₃H₂, -NHPO₃H₂, -NHCOCF₃, -NHCO₂CF₃, -CONHNHCO₂CF₃, -C(CF₃)₂OH, -SO₂NHR^{12a}, -CONHSO₂NHR^{12a}, -SO₂NHCOR^{12a}, -SO₂NHCO₂R^{12a}, -CONHSO₂R^{12b},

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

$-\text{NHSO}_2\text{R}^{12b}$, $-\text{CONHOR}^{12b}$,



each R^{12a} is, independently at each occurrence, H, C_{1-6} alkyl, or $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocycle substituted with 0-3 R^d ; ~~or $-(\text{CH}_2)_r\text{-5-10}$ membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $\text{S}(\text{O})_p$, and substituted with 0-3 R^d ;~~

each R^{12b} is, independently at each occurrence, $\text{C}_1\text{-C}_6$ alkyl substituted with 0-2 R^{12c} , $\text{C}_2\text{-C}_6$ alkenyl substituted with 0-2 R^{12c} , $\text{C}_2\text{-C}_6$ alkynyl substituted with 0-2 R^{12c} , or $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocycle substituted with 0-3 R^{12c} ; ~~or $-(\text{CH}_2)_r\text{-5-10}$ membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $\text{S}(\text{O})_p$, and substituted with 0-3 R^{12c} ;~~

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3 , OCF_3 , CN, NO_2 , OR^a , $-\text{CO}_2\text{R}^a$, $-\text{NR}^7\text{R}^8$, $-\text{SO}_2\text{R}^c$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, or $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocycle substituted with 0-3 R^d ; ~~or $-(\text{CH}_2)_r\text{-5-10}$ membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $\text{S}(\text{O})_p$, and substituted with 0-3 R^d ;~~

R^{13} is H or C_{1-4} alkyl;

R^{14} is H or C_{1-4} alkyl;

R^{16} is H, C_{1-4} alkyl, benzyl, C_{1-4} alkyl- $\text{C}(\text{O})-$, C_{1-4} alkyl- $\text{S}(\text{O})_2-$, or C_{1-4} alkyl- $\text{OC}(\text{O})-$;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, $-(\text{CH}_2)_r\text{-CO}_2\text{R}^g$, $-(\text{CH}_2)_r\text{-C}_{3-7}$ cycloalkyl, or $-(\text{CH}_2)_r\text{-C}_{6-10}$ aryl, wherein said aryl is substituted with 0-2 R^f ;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

each R^b is, independently at each occurrence, CF_3 , OH, C_{1-4} alkoxy, C_{1-6} alkyl, or $-(CH_2)_r-C_{3-10}$ carbocycle substituted with 0-2 R^d ;

each R^c is, independently at each occurrence, C_{1-4} alkyl, C_{6-10} aryl, or $(C_{6-10}$ aryl)- C_{1-4} alkyl;

each R^d is, independently at each occurrence, H, =O, OR^a , F, Cl, Br, I, CN, NO_2 , $-NR^7R^8$, $-C(O)R^a$, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-C(O)NR^7R^8$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$ -phenyl, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, $-S(O)_p$ -phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl substituted with 0-2 R^e , C_2-C_6 alkenyl substituted with 0-2 R^e , or C_2-C_6 alkynyl substituted with 0-2 R^e ;

each R^e is, independently at each occurrence, =O, OR^a , F, Cl, Br, I, CN, NO_2 , $-NR^8R^9$, $-C(O)R^a$, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-C(O)NR^7R^8$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$ -phenyl, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, $-S(O)_p$ -phenyl, or $-(CF_2)_rCF_3$;

each R^f is, independently at each occurrence, H, =O, OR^g , F, Cl, Br, I, CN, NO_2 , $-NR^8R^9$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$ -phenyl, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, $-S(O)_p$ -phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$ -phenyl;

n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;

provided that ~~A is phenyl or a 6-membered aromatic N-heterocycle, then~~ ring


A is not substituted ortho to the tetrahydroquinoline with OH, halogen, $-CO_2H$,

$-C(O)O-C_{1-4}$ alkyl, $-O$ -phenyl, $-O$ -benzyl, $-NR^7R^8$, $-CH_2OR^a$, haloalkyl, $-S-C_{1-4}$ alkyl,

or $-NH-SO_2-C_{1-4}$ alkyl.

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

3. (Currently amended) A compound according to Claim 2, wherein the compound is of Formula (Ib):



(Ib)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12} ;

R^1 is H, F, Cl, $-C(=NH)NH_2$, $-CH_2NH_2$, $-C(O)NR^{7a}R^8$, OMe, or CN;

R^4 is H, $-(CH_2)_r$ -C₃-C₇ cycloalkyl substituted with 0-2 R^{4b} , or $-(CH_2)_r$ -phenyl substituted with 0-3 R^{4b} ;

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Br, CN, NO₂, CF₃, $-C(O)OR^a$, $-SO_2R^c$, $-NR^7R^8$, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ haloalkyloxy-, C₁-C₄ alkyloxy-, C₁-C₄ alkylthio-, C₁-C₄ alkyl-C(O)-, or C₁-C₄ alkyl-C(O)NH-;

R^5 is H, C₁-C₃ alkyl, or C₃-C₆ cycloalkyl;

each R^7 is, independently at each occurrence, H, C₁₋₆ alkyl, or benzyl;

each R^{7a} is, independently at each occurrence, H, C₁₋₄ alkyl substituted with 0-1 R^{7b} or 0-1 R^{7c} , $-(CH_2)_r$ -C₃₋₇ cycloalkyl substituted with 0-1 R^f , or $-(CH_2)_r$ -phenyl substituted with 0-2 R^f ;

each R^{7b} is, independently at each occurrence, OR^g , F, CN, $-NR^7R^8$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-SO_2NR^8R^9$, or $-NR^8SO_2$ -C₁₋₄ alkyl;

R^{7c} is C₃₋₇ cycloalkyl substituted with 0-1 R^f , or phenyl substituted with 0-2 R^f ;

each R^8 is, independently at each occurrence, H, C₁₋₆ alkyl, or benzyl;

each R^9 is, independently at each occurrence, H, C₁₋₆ alkyl, or benzyl;

each R^{11} is, independently at each occurrence, H, F, $-(CH_2)_r$ -OR^a, CN, $-(CH_2)_r$ -NR⁷R⁸, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-NR^8C(O)OR^a$, $-C(O)NR^{7a}R^8$,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

$-\text{NR}^8\text{C}(\text{O})\text{NR}^8\text{R}^9$, $-\text{SO}_2\text{NR}^8\text{R}^9$, or $-\text{NR}^8\text{SO}_2\text{-C}_{1-4}$ alkyl;

R^{12} is $-\text{C}(\text{O})\text{NR}^7\text{R}^8$, $-(\text{CH}_2)_r\text{CO}_2\text{R}^{12a}$, $-\text{SO}_2\text{NHR}^{12a}$, $-\text{CONHSO}_2\text{NHR}^{12a}$,
 $-\text{SO}_2\text{NHCOR}^{12a}$, $-\text{SO}_2\text{NHCO}_2\text{R}^{12a}$, $-\text{CONHSO}_2\text{R}^{12b}$, $-\text{NHSO}_2\text{R}^{12b}$,
 $-\text{CONHSO}_2\text{R}^{12b}$, $-\text{CONHOR}^{12b}$, or $-(\text{CH}_2)_r\text{-5-tetrazolyl-}$;

each R^{12a} is, independently at each occurrence, H or C_{1-6} alkyl;

each R^{12b} is, independently at each occurrence, $\text{C}_1\text{-C}_4$ alkyl substituted with 0-1
 R^{12c} , $\text{C}_2\text{-C}_4$ alkenyl substituted with 0-1 R^{12c} , $\text{C}_2\text{-C}_4$ alkynyl substituted with 0-1 R^{12c} ,
or $-(\text{CH}_2)_r\text{-C}_3\text{-C}_7$ carbocycle substituted with 0-2 R^{12c} , ~~or $-(\text{CH}_2)_r\text{-5-6 membered}$~~
~~heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the~~
~~group consisting of N, O, and S(O)_p, and substituted with 0-2 R^{12c} ;~~

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3 , OCF_3 , CN,
 NO_2 , OR^a , $-\text{CO}_2\text{R}^a$, $-\text{NR}^7\text{R}^8$, $-\text{SO}_2\text{R}^c$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, or
 $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocycle substituted with 0-3 R^d , ~~or $-(\text{CH}_2)_r\text{-5-10 membered}$~~
~~heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group~~
~~consisting of N, O, and S(O)_p, and substituted with 0-3 R^d ;~~

R^{13} is H or $\text{C}_1\text{-C}_4$ alkyl;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, $-(\text{CH}_2)_r\text{-CO}_2\text{R}^g$,
 $-(\text{CH}_2)_r\text{-C}_{3-7}$ cycloalkyl, or $-(\text{CH}_2)_r\text{-C}_{6-10}$ aryl;

each R^f is, independently at each occurrence, H, =O, OR^g , F, Cl, Br, CF_3 , CN,
 NO_2 , $-\text{NR}^8\text{R}^9$, $-\text{C}(\text{O})\text{R}^g$, $-\text{C}(\text{O})\text{OR}^g$, $-\text{NR}^8\text{C}(\text{O})\text{R}^g$, $-\text{C}(\text{O})\text{NR}^8\text{R}^9$, $-\text{SO}_2\text{NR}^8\text{R}^9$,
 $-\text{NR}^8\text{SO}_2\text{-C}_{1-4}$ alkyl, $-\text{NR}^8\text{SO}_2\text{CF}_3$, $-\text{S}(\text{O})_2\text{CF}_3$, $-\text{S}(\text{O})_p\text{-C}_{1-4}$ alkyl, $\text{C}_1\text{-C}_6$ alkyl,
 $\text{C}_2\text{-C}_6$ alkenyl, or $\text{C}_2\text{-C}_6$ alkynyl;

each R^g is, independently at each occurrence, H or C_{1-4} alkyl;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

provided ring A is not substituted ortho to its attachment to the
tetrahydroquinoline with OH, $-\text{CO}_2\text{H}$, $-\text{C}(\text{O})\text{O-C}_{1-4}$ alkyl, O-phenyl, O-benzyl, $-\text{NR}^7\text{R}^8$,
or $-\text{NHSO}_2\text{C}_{1-4}$ alkyl.

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

4. (Currently amended) A compound according to Claim 3, wherein:

A is phenyl substituted with 0-2 R¹¹;

B is phenyl substituted with 0-2 R¹¹ and 0-1 R¹²;

R¹ is -C(=NH)NH₂, -C(=O)NH₂, -CH₂NH₂, or OMe;

R⁴ is phenyl substituted with 0-1 R^{4b};

R^{4b} is H, OH, or F;

R⁵ is H, Me, Et, or Pr;

each R¹¹ is, independently at each occurrence, H, F, OH, OMe, CN, -NH₂, -CH₂OH, -CO₂H, -CO₂Me, -NHCOMe, -NHCOEt, -NHCOPr, -NHCO(i-Pr), -NHCO(i-Bu), -NHCO(cyclopropyl), -NHCO(phenyl), -NHCO(2-CO₂H-phenyl), -NHCO(3-CO₂H-phenyl), -NHCO(4-CO₂H-phenyl), -NHCO(3,5-(CO₂H)₂-phenyl), -NHCO(3,5-(CF₃)₂-phenyl), -NHCO(3-Me-5-CO₂H-phenyl), -NHCO(3-(t-Bu)-5-CO₂H-phenyl), -NHCO(3-CONH₂-5-CO₂H-phenyl), -NHCO(3-NH₂-5-CO₂H-phenyl), -NHCO(benzyl), -NHCO(phenethyl), -NHCO(phenylpropyl), -NHCO[2-(2-pyridyl)-ethyl], -NHCO(tetrazol-5-yl), -NHCOCH₂(tetrazol-5-yl), -NHCO(CH₂)₂(tetrazol-5-yl), -CONH₂, -CONHMe, -CONH(i-Pr), -CONH(i-Bu), -CONH(t-Bu), -CONH(benzyl), -CONH(phenethyl), -CONH(phenylpropyl), -CONH[2-(2-pyridyl)-ethyl], -NHCONHMe, -NHCONHEt, -NHCH₂CO₂H, -NHCOCO₂H, -NHCOCH₂CO₂H, -NHCO(CH₂)₂CO₂H, -NHCO(CH₂)₃CO₂H, -NHSO₂Me, -NHSO₂Et, or -CH₂NMe₂;

R¹² is -CO₂H, -CH₂(CO₂H), -CO₂Me, -SO₂NH₂, or -CONH₂; and

R¹³ is H or Me; and

provided ring A is not substituted ortho to its attachment to the tetrahydroquinoline with OH, -CO₂H, -CO₂Me, -NH₂, or -NHSO₂C₁₋₄ alkyl.

5. (Original) A compound according to Claim 4, wherein:

A is 1,2-phenylene, 4-OMe-1,2-phenylene, 3-CO₂H-1,2-phenylene, 4-OMe-5-OH-1,2-phenylene, 5-CH₂OH-1,2-phenylene, 5-NHCOMe-1,2-phenylene,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

5-phenylcarbamoyl-1,2-phenylene, 5-benzylcarbamoyl-1,2-phenylene,
5-phenethylcarbamoyl-1,2-phenylene, 5-(3-phenylpropylcarbamoyl)-1,2-phenylene,
5-[2-(2-pyridyl)ethylcarbamoyl]-1,2-phenylene, 5-NHCO(i-Bu)-1,2-phenylene,
1,3-phenylene, 6-OMe-1,3-phenylene, 6-F-1,3-phenylene, 5-NH₂-1,3-phenylene,
5-NHCOMe-1,3-phenylene, 5-NHCOEt-1,3-phenylene, 5-NHCOPr-1,3-phenylene,
5-NHCO(i-Pr)-1,3-phenylene, 5-NHCO(i-Bu)-1,3-phenylene,
5-NHCO(cyclopropyl)-1,3-phenylene, 5-NHCONHEt-1,3-phenylene,
5-NHCOCO₂H-1,3-phenylene, 5-NHCOCH₂CO₂H-1,3-phenylene,
5-NHCO(CH₂)₂CO₂H-1,3-phenylene, 5-NHCO(CH₂)₃CO₂H-1,3-phenylene,
5-NHCO(phenyl)-1,3-phenylene, 5-NHCO(benzyl)-1,3-phenylene,
5-NHCO(2-CO₂H-phenyl)-1,3-phenylene, 5-NHCO(3-CO₂H-phenyl)-1,3-phenylene,
5-NHCO(4-CO₂H-phenyl)-1,3-phenylene,
5-NHCO(3,5-(CO₂H)₂-phenyl)-1,3-phenylene,
5-NHCO(3,5-(CF₃)₂-phenyl)-1,3-phenylene,
5-NHCO(3-Me-5-CO₂H-phenyl)-1,3-phenylene,
5-NHCO(3-(t-Bu)-5-CO₂H-phenyl)-1,3-phenylene,
5-NHCO(3-CONH₂-5-CO₂H-phenyl)-1,3-phenylene,
5-NHCO(3-NH₂-5-CO₂H-phenyl)-1,3-phenylene,
5-NHCO(tetrazol-5-yl)-1,3-phenylene, 5-NHCOCH₂(tetrazol-5-yl)-1,3-phenylene,
5-NHCO(CH₂)₂(tetrazol-5-yl)-1,3-phenylene, 5-NHSO₂Et-1,3-phenylene,
5-NHCH₂CO₂H-1,3-phenylene, or 3-CO₂H-1,4-phenylene;

B is 2-CO₂H-phenyl, 4-CO₂H-phenyl, 2-SO₂NH₂-phenyl,
3-CH₂(CO₂H)-phenyl, 2,4-(CO₂H)₂-phenyl, 2,4-(CO₂Me)₂-phenyl,
2,4-(CONH₂)₂-phenyl, 2-CO₂H-4-CO₂Me-phenyl, 2-CO₂H-4-NH₂-phenyl,
2-CO₂H-4-CN-phenyl, 2-CO₂H-4-OMe-phenyl, 2-CO₂H-4-NHAc-phenyl,
2-CO₂H-4-CONH₂-phenyl, 2-CO₂H-4-CONH(i-Pr)-phenyl,
2-CO₂H-4-C(O)NH(i-Bu)-phenyl, 2-CO₂H-4-C(O)NH(t-Bu)-phenyl,
2-CO₂H-4-NHCOMe-phenyl, 2-CO₂H-4-NHCONHMe-phenyl,

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

2-CO₂H-4-CH₂NMe₂-phenyl, or 2-CO₂H-4-NHSO₂Me-phenyl;

R¹ is -C(=NH)NH₂, -C(=O)NH₂, -CH₂NH₂, or OMe;

R⁴ is phenyl, 4-OH-phenyl or 4-F-phenyl;

R⁵ is H, Me, Et, or Pr; and

R¹³ is H or Me.

6. (Original) A compound of Claim 1 selected from:

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-5'-hydroxy-4'-methoxy-biphenyl-2-carboxylic acid;

2'-[6-carbamimidoyl-4-(4-hydroxy-phenyl)-1,2,3,4-tetrahydro-quinolin-2-yl]-5'-hydroxy-4-isobutylcarbamoyl-4'-methoxy-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid dimethyl ester;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-4-carboxylic acid;

2'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid dimethyl ester;

2'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-t-butylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;
4-phenyl-2-(2'-sulfamoyl-biphenyl-3-yl)-1,2,3,4-tetrahydro-quinoline-6-carboxamidine;
4-methyl-4-phenyl-2-(2'-sulfamoyl-biphenyl-3-yl)-1,2,3,4-tetrahydro-quinoline-6-carboxamidine;
3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid 4-methyl ester;
3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid diamide;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;
3'-(6-carbamimidoyl-4-ethyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;
3'-(6-carbamimidoyl-4-propyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;
4-amino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-(3-methyl-ureido)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methanesulfonylamino-biphenyl-2-carboxylic acid;
4-acetylamino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-cyano-biphenyl-2-carboxylic acid;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-
biphenyl-2,4-dicarboxylic acid 4-methyl ester;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-
biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-
methylcarbamoyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-
isopropylcarbamoyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-t-
butylcarbamoyl-biphenyl-2-carboxylic acid;
3'-[6-carbamimidoyl-4-(4-fluoro-phenyl)-4-methyl-1,2,3,4-tetrahydro-quinolin-2-
yl]-4-carbamoyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-
dimethylaminomethyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-3-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-
carbamoyl-biphenyl-2-carboxylic acid;
5'-amino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-
yl)-4-carbamoyl-biphenyl-2-carboxylic acid;
5'-amino-3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-
biphenyl-2-carboxylic acid;
5'-acetylamino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-
quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-
carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;
4-carbamoyl-3'-(6-carbamoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-
yl)-biphenyl-2-carboxylic acid;
4-carbamoyl-3'-(6-methoxy-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-
biphenyl-2-carboxylic acid;
3'-(6-aminomethyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-
carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

3'-(6-aminomethyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(n-propanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(cyclopropylcarbonylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methoxyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-4'-methoxy-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-4'-fluoro-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-carboxyproacetyl amino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(carboxycarbonylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(benzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-phenylacetyl amino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxypropanoylamino)-biphenyl-2-carboxylic acid;

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(4-carboxybenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxybenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-carboxybenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(carboxymethylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3,5-bis(carboxybenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[(5-tetrazolyl)methylcarbonylamino]-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(4-carboxybutyrylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[(5-tetrazolyl)carbonylamino]-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3,5-bisfluorobenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-amino-5-carboxybenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[2-(5-tetrazolyl)ethylcarbonylamino]-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxy-5-methylbenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxy-5-t-butylbenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-aminocarbonyl-5-carboxybenzoylamino)-biphenyl-2-carboxylic acid;
3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(ethylaminocarbonylamino)-biphenyl-2-carboxylic acid; and

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(ethylsulfonylamino)-biphenyl-2-carboxylic acid;
or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof.

7. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

8. (Original) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

9. (Original) A method according to Claim 8, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

10. (Original) A method according to Claim 9, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

11-23. (Canceled)

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

24. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.
25. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.
26. (Previously presented) A method according to Claim 25, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.
27. (Previously presented) A method according to Claim 26, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
28. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.
29. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

30. (Previously presented) A method according to Claim 29, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.
31. (Previously presented) A method according to Claim 30, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
32. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.
33. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.
34. (Previously presented) A method according to Claim 33, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

35. (Previously presented) A method according to Claim 34, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
36. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.
37. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.
38. (Previously presented) A method according to Claim 37, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.
39. (Previously presented) A method according to Claim 38, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other

U.S. Serial No. 10/796,396
Docket No.: PH-7493-NP

implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

40. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

41. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

42. (Previously presented) A method according to Claim 41, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

43. (Previously presented) A method according to Claim 42, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.